Solutions

wellcome.ac.uk - November 28, 2014

A rapid, point-of-care diagnostic test for the Ebola virus will be trialled in the coming weeks at the Ebola treatment centre in Conakry, Guinea. The trial is one of six health research projects that have been jointly funded by the Wellcome Trust and the UK government.

The 15-minute Ebola test is six times faster than similar tests currently in use and aims to speed up the diagnosis of Ebola cases. Early detection of Ebola leads to better infection control as medical staff can identify and isolate confirmed cases of Ebola faster, and start treating patients sooner. Ultimately, a faster test could reduce Ebola transmission and mortality.

The project is supported through a joint Department for International Development (DFID) and Wellcome Trust fund for rapid health research during the Ebola outbreak. The six projects are managed by Enhancing Learning & Research for Humanitarian Assistance (ELRHA).

By Kevin Sieff -  November 27 2014 - washingtonpost.com

The doctor who treated Martin Salia, the Sierra Leonean physican who died of Ebola last week after being transported to Omaha, has contracted the disease himself.

Komba Songu M’Briwa cared for Salia, his colleague and former professor, at Freetown’s Hastings Ebola Treatment Center before Salia, whose family lives in New Carrollton, was transported to the United States.

After Salia’s initial Ebola test came back negative, M’Briwa said employees “were celebrating” by embracing him. Salia’s subsequent test came back positive, meaning they had been unknowingly exposed to the virus.

It’s not certain that was how M’Briwa contracted Ebola.

http://www.washingtonpost.com/world/sierra-leone-physician-who-treated-martin-salia-diagnosed-with-ebola/2014/11/27/af1fbd54-7627-11e4-a755-e32227229e7b_story.html

SCIENCE        By Jon Cohen                                                                                         Nov. 21, 2014

...Just a handful of basic interventions to fight the killer effects of Ebola, including dehydration and secondary infections, could dramatically lower the CFR there, says Michael Callahan, an infectious disease specialist at Massachusetts General Hospital in Boston..

With so much room for improvement in supportive care, the current international focus on drugs is “misguided,” says Callahan, who has recently worked in Monrovia and provided care in four previous Ebola outbreaks. “While we wait for months for forthcoming experimental therapies, many lives can be saved, certainly hundreds and possibly thousands, using inexpensive and simple therapies,” he says.

Callahan is helping an international team develop guidelines dubbed Maximum Use of Supportive Therapy (MUST), aimed at keeping more patients alive. It includes intravenous (IV) drips to replace massive fluid loss from diarrhea and vomiting, a risk factor for shock; balancing of electrolytes such as calcium or potassium, which prevents kidney and heart failure; nasogastric tubes for feeding; and testing and treatment of secondary infections such as malaria. Introducing MUST will also make it easier to study new treatments, Callahan says...

TIME MAGAZINE By Alexandra Sifferlin                          Nov. 25, 2014
 By  Alexandra Sifferlin                       

Scientists are scurrying to get their Ebola vaccines through the necessary safety trials before they can be used widely. That includes the University of Maryland School of Medicine, which recently kicked off the latest step in their research: figuring out the appropriate dosing for the vaccine that’s both effective and safe.

The University of Maryland is one of a handful of institutions involved in the testing of an experimental but promising vaccine developed by the National Institutes of Health’s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK). The hope is that the vaccine will pass through early trials needed by end of December so that the World Health Organization (WHO) and a panel of outside experts can decide whether to move on to a large efficacy trial, which would mean vaccinating a lot of people in West Africa to see how well it works.